

1 **Title: Supplementation with short-chain fatty acids and the prebiotic 2FL**
2 **improves clinical outcome in PD**

3
4 **Authors:** Tobias Hegelmaier, MD^{1†}, Alexander Duscha, MSc^{1†}, Christiane Desel, PhD^{1†},
5 Sabrina Fuchs¹, Michal Shapira, PhD^{3,4}, Qihao Shan, MSc⁵, Gabriele I Stangl, MD⁶, Frank
6 Hirche, PhD⁶, Stefan Kempa, PhD⁷, András Maifeld, MD, PhD⁷, Lisa-Marie Würtele⁸, Jana
7 Peplinski⁸, Diana Jauk⁸, Claudia A. Dumitru, PhD⁹, Ute Obermüller-Jevic, PhD¹⁰, Svein-Olaf
8 Hustvedt¹¹, Nina Timmesfeld, PhD¹², Ralf Gold, MD⁸, Antonia Zapf, PhD¹³, Ibrahim E.
9 Sandalcioglu, MD⁹, Sanaz Mostaghim, PhD⁵, Horst Przuntek, MD¹⁴, Eran Segal, PhD^{3,4}, Nissan
10 Yissachar, PhD^{15, ‡}, Aiden Haghikia, MD^{1,2, ‡,*}

11 **Affiliations:**

12 ¹ Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.

13 ² German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.

14 ³ Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

15 ⁴ Department of Computer Science and Applied Mathematics, Weizmann Institute of Science,
16 Rehovot, Israel.

17 ⁵ Faculty of Computer Science, Otto-von-Guericke University Magdeburg, Magdeburg,
18 Germany.

19 ⁶ Institute of Agricultural and Nutritional Sciences, Martin-Luther-University Halle-Wittenberg,
20 Halle (Saale), Germany.

21 ⁷ Integrative Metabolomics and Proteomics, Berlin Institute of Medical Systems Biology/Max
22 Delbrück Center for Molecular Medicine, Berlin, Germany.

23 ⁸ Department of Neurology, Ruhr University Bochum, St. Josef Hospital Bochum, Bochum,
24 Germany.

25 ⁹ Department for Neurosurgery, Otto-von-Guericke University, Magdeburg, Germany.

26 ¹⁰ Nutrition & Health Division, GBU Nutrition Ingredients, BASF SE, Ludwigshafen, Germany.

27 ¹¹ Nutrition & Health Division, GBU Pharma Solutions, BASF A/S, Oslo, Norway.

28 ¹² Department for Medical Informatics, Biometry and Epidemiology, Ruhr-University, Bochum,
29 Germany.

30 ¹³ Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-
31 Eppendorf, Hamburg, Germany.

32 ¹⁴ Clinic of Neurology II, EVK Hattingen, Hattingen, Germany.

33 ¹⁵ The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan,
34 Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University,
35 Ramat-Gan, Israel.

36 †equally contributing first authors

37 ‡equally contributing authors

38 *Corresponding author:

39 Aiden Haghikia, Dpt. Neurology, Otto-von-Guericke University, Leipziger Str. 44, 39120
40 Magdeburg, Germany, +49-391-6713431, aiden.haghikia@med.ovgu.de

41 **Running Title:**

42 SCFA supplementation in PD.

43 **Financial Disclosure/Conflict of Interest:**

44 Competing interests: U. O.-J. is an employee of BASF SE, Ludwigshafen, Germany. S.-O. H. is
45 an employee of BASF A/S, Oslo, Norway. A. H. and R. G. have filed a patent on the supportive
46 immunomodulatory effect of C3-C8 aliphatic fatty acids. A. H. and H. P. have filed a patent on
47 the prophylactic and/or supportive therapeutic treatment of PD. The other authors declare no
48 competing interests.

49 **ABSTRACT**

50 Background: Parkinson's disease (PD) is associated with dysbiosis, proinflammatory gut
51 microbiome, disruptions to intestinal barrier functions, and immunological imbalance. Microbiota-
52 produced short-chain fatty acids promote gut barrier integrity and immune regulation, but their
53 impact on PD pathology remains mostly unknown.

54 Objectives: To evaluate supplementation with short-chain fatty acids as an add-on intervention in
55 PD.

56 Methods: In a randomized double-blind prospective study, 72 PD patients received short-chain
57 fatty acids and/or the prebiotic fiber 2'-fucosyllactose supplementation over 6 months.

58 Results: We observed improvement in motor and nonmotor symptoms, in addition to modulation
59 of peripheral immunity and improved mitochondrial respiration in immunocytes. The
60 supplementation had no effect on microbiome diversity or composition. Finally, multiobjective
61 analysis and comprehensive immunophenotyping revealed parameters associated with an optimal
62 response to short-chain fatty acids and/or 2'-fucosyllactose supplementation.

63 Conclusion: Short-chain fatty acids ameliorate clinical symptoms in Parkinson's disease patients
64 and modulate mitochondrial function and peripheral immunity.

65 INTRODUCTION

66 Parkinson's disease (PD) is one of the most common progressive systemic neurodegenerative
67 disorders, affecting millions of people worldwide. Despite intensive research, the cause of
68 neurodegeneration is not fully understood. The current state of research assumes a multifactorial
69 etiology. In addition to sporadic forms of genetic predisposition, mitochondrial dysfunction,
70 oxidative stress and neuroinflammation, also environmental factors play a crucial role.¹
71 Gastrointestinal symptoms are often the first nonmotor symptoms in PD, in addition to olfactory
72 dysfunction, which in most cases occur years to decades before the first motor symptoms, i.e.,
73 rigor, tremor and akinesia.² PD incidence rates are rising in addition to changes in nutrition and
74 the consumption of Western-style diets, which are low in fiber and high in saturated fats and
75 refined carbohydrates. These dietary habits lead to a dysbiotic intestinal microbiota and altered
76 metabolome as well as intestinal inflammation.³ Growing evidence supports the idea that microbial
77 dysbiosis, leaky gut syndrome and a proinflammatory intestinal environment are central
78 components of the pathogenesis of PD.⁴⁻⁷

79 The gut metabolome is essential for metabolic homeostasis but is also involved in communication
80 between the microbiome and the subepithelial structures of the gut, which has multifold systemic
81 implications for the organism. Short-chain fatty acids (SCFAs) are a major group of metabolites
82 involved in the microbiome-gut interaction and are produced through the anaerobic fermentation
83 of dietary fibers. A large proportion of SCFAs are metabolized by colonocytes or in the liver,
84 where they contribute to the energy supply. However, a broad range of intracellular SCFA effects
85 are also mediated by G-protein-coupled receptors and SCFA transporters. These include

86 maintenance of intestinal barrier integrity, mucus production, protection against intestinal and
87 systemic inflammation and blood–brain barrier (BBB) permeability.⁸ In PD patients, the levels of
88 SCFA-producing bacteria and fecal SCFAs are significantly reduced.⁹ In a recent study
89 investigating the potential therapeutic effect of propionate (PA), we observed a putative
90 neuroprotective effect in addition to immune regulation.¹⁰ Targeting the gut-brain axis via the
91 microbiome, metabolome and intestinal barrier is a promising approach for future therapies for
92 PD. Consumption of prebiotic fibers has recently been tested in a small cohort of PD patients over
93 10 days.¹¹ However, SCFA supplementation in PD patients over a prolonged period has not yet
94 been evaluated.

95 Here, we conducted a randomized, double-blind prospective study over 6 months to investigate
96 direct supplementation of the SCFAs PA and butyric acid (BA) and the prebiotic 2'-fucosyllactose
97 (2FL).¹² The primary endpoints of this study were the impact on microbiome diversity and
98 composition as well as changes of SCFA concentration in stool and serum. Because the study was
99 exploratory, no correction for multiplicity and no confirmatory statements are made. The
100 secondary endpoints were the effect on the clinical parameters defined by The Movement Disorder
101 Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS III),
102 levodopa equivalent daily dose (LEDD), PANDA, and olfactory score. We identified novel
103 mechanistic connections between SCFA supplementation, systemic immunity and clinical
104 outcomes in PD patients.

105 **METHODS**

106 **Study design and analysis**

107 The study was performed from November 2019 to August 2020 after being approved by the Ethics
108 Committee of the Ruhr-University Bochum (November 2019; registration number 19-6713). Prior

109 to participation, all subjects signed informed consent forms. This clinical trial was registered in
110 the German Clinical Trials Register (DRKS; registration number DRKS00027061). A total of 94
111 participants were assessed for eligibility and 72 were confirmed for randomization and assigned
112 to one treatment group upon recruitment. Randomization was performed by permuted block
113 randomization to one of the three study arms. The randomization list was prepared by BASF SE
114 and provided to the hospital pharmacy in a sealed envelope. All patients were instructed to take
115 either 3810 mg PA+BA capsules (BA: 2550 mg; PA: 1260 mg) with 2400 mg placebo, 3250 mg
116 2FL capsules with 3200 mg placebo or 3250 mg 2FL capsules with 3810 mg PA+BA capsules
117 daily for up to 6 months in combination with existing PD-specific therapy. The PA+BA, 2FL and
118 placebo were provided as delayed-release capsules by BASF SE. Individual subjects were seen at
119 the outpatient clinic every 3 months after initiation of supplementation and underwent complete
120 neurological assessment performed by a certified Neurostatus C neurologist. Blood and fecal
121 samples were collected at the Department of Neurology, St. Josef Hospital Bochum, at the Clinic
122 of Neurology II, EVK Hattingen, and at the University Clinic of Neurology, UK Magdeburg.
123 Clinical data were evaluated by 2-way ANOVA with time and treatment as factors or mixed effects
124 analysis with patient as random effect. It was not corrected for multiplicity, so the p-values are
125 used as descriptive measures. Fecal samples were immediately frozen at -80°C. Serum tubes were
126 centrifuged at 30 min after the blood draw, and the supernatant frozen at -80°C. For isolation of
127 PBMCs, blood was drawn in EDTA tubes and separated using Cytiva Ficoll-Paque™ PLUS.
128 Isolated cells were frozen in CTL-Cryo medium (Immunospot) and stored at -80°C.

129 **Quantification of SCFA levels in serum and fecal samples**

130 Methods of sample preparation were previously described.¹⁰ SCFA levels were measured by
131 HPLC–MS/MS (Agilent 1100 HPLC).

132 **Metagenomic sequencing and bioinformatics analysis**

133 Metagenomic DNA was extracted using the DNeasy PowerMag Soil DNA extraction kit (Qiagen).
134 Next-generation sequencing (NGS) libraries were prepared using Illumina's Nextera DNA library
135 prep and sequenced on an Illumina NovaSeq sequencing platform with 100 bp single-end reads at
136 a depth of 10 million reads per sample. Reads containing Illumina adapters and low-quality reads
137 were filtered out, and ends of low-quality reads trimmed. Reads were mapped to the human
138 genome using bowtie with inclusive parameters, and matches were discarded. The relative
139 abundance of bacterial species was obtained by an expanded microbial genome reference,¹³ with
140 default parameters. Microbiome α -diversity was calculated by the Shannon diversity index.
141 Richness was calculated as the number of species in the sample detected with an abundance of at
142 least $1e-4$. All abundances were logarithmically transformed. To evaluate the discriminative power
143 of microbial composition for response prediction, we developed an XGBoost¹⁴ prediction model
144 that exclusively utilizes microbiome features as inputs and outperforms other methods for human
145 microbiome data classification.¹⁵ The receiver operating characteristic (ROC) curves mean and
146 standard deviation were calculated using the curves produced in a fivefold cross-validation
147 approach. To ensure the model's robustness, we conducted a label-swapping analysis to determine
148 that the performance of the model was no better than random prediction, resulting in an area under
149 the curve (AUC) value very close to 0.5. To gain insights into the model's interpretability, we
150 utilized SHAP (SHapley Additive explanation)¹⁶ to analyze feature attributes. The SHAP values
151 represent the average change in the model's output when conditioning on a specific feature.

152 **Immunophenotyping**

153 For in-depth immunophenotyping archived PBMCs were stained according to standard protocols.
154 Antibodies used and gating strategies applied are listed in Supplementary Tables S1,S2. Staining

155 panels and gatings were modified based on Monaco et al.¹⁷ Data was recorded on a BD
156 FACSCelesta™ with standardized application settings.

157 **Treg *in vitro* assays**

158 Treg suppression assays were performed as previously described¹⁰ using whole blood from a
159 validation cohort of PD patients at baseline and after 14 days of supplementation with 2FL or
160 BA+PA. For Treg/PBMC cocultures with *in vitro* addition of BA and PA, blood from healthy
161 controls or PD patients without SCFA supplementation was used. Treg/PBMC cells were isolated
162 as described and seeded on a 1:1 ratio in serum free TheraPEAK™ X-VIVO™ 15 (Lonza) without
163 CFSE staining. Cells were stimulated with 5 µg/ml PHA (Phytohemagglutinin, Merck), 150 µM
164 BA (Merck) and 150 µM PA (Merck) for 4 days. Cell culture supernatants were analyzed using a
165 LEGENDplex™ Human Essential Immune Response Panel (BioLegend) and recoded on a BD
166 FACSCelesta™.

167 **qPCR analysis of sorted Tregs**

168 PBMCs from the validation cohort were isolated and 5×10^7 cells stained with αCD4-FITC
169 (RPAT4, BD Biosciences), αCD25-APC (BC69, BioLegend) and αCD127-PE (HIL-7R-M21, BD
170 Biosciences). CD4⁺CD25⁺CD127^{lo} Tregs were sorted on a BD FACSAria™ III. RNA was
171 isolated using an RNeasy Micro kit (Qiagen) and transcribed using a QuantiTect® Reverse
172 Transcription Kit (Qiagen). QPCR was performed on a QuantStudio™ 7 Real-Time PCR system
173 using TaqMan® Fast Advanced Master Mix and TaqMan® Gene Expression assays (Applied
174 Biosystems): *B2m*: Hs00187842_m1, *Ccr8*: Hs04969449_m1, *Cmcl1*: Hs00976539_g1, *Crot*:
175 Hs00221733_m1, *Ctla4*: Hs00175480_m1, *Foxp3*: Hs01085834_m1, *Il10*: Hs00961622_m1,
176 *Il17rb*: Hs00218889_m1, *Xpa*: Hs00902270_m1.

177 **Seahorse XF Cell Mito Stress Test**

178 Cellular metabolic activity was measured using a Seahorse XFp Cell Mito Stress Test Kit (Agilent
179 Technologies) on a Seahorse XFp analyzer according to the manufacturer's protocol. Frozen
180 PBMCs were thawed and 3×10^5 cells per well were seeded on poly-D-lysine-coated 6-well Agilent
181 Seahorse XF Cell Culture Microplates in X-VIVO™ 15 (Lonza). Cells were incubated for 24 h at
182 37°C prior to Seahorse assay performance. Individual parameters were calculated according to the
183 Seahorse XFp Cell Mito stress test protocol.

184 **Multiobjective analysis**

185 Multiobjective analysis (MOA) is based on the concept of multiobjective optimization and is
186 applied to problems with several conflicting objectives, where increasing the quality in one
187 objective results in deteriorating the others. Multiobjective problems usually contain a subset of
188 data points that are not dominated by others in the dataset and are located on a front surface if
189 mapped to the objective space. The central idea concerns the nondominated sorting of a dataset¹⁸
190 and then clustering the data according to the so-called fronts. The clinical dataset A of N patients,
191 was sorted according to the domination criterion as follows: A data point X dominates a data point
192 Y given the objectives $f_1 = \text{PANDA}$, $f_2 = \text{MDS-UPDRSIII}$ and $f_3 = \text{olfactory score}$ if:

$$193 \quad f_i(X) \leq f_i(Y), \forall i \text{ and } \exists j: f_j(X) < f_j(Y)$$

194 where $<$ and \leq denote better and equal or better, respectively.

195 By applying the domination criterion to the dataset A , a subset of data points that are not dominated
196 by any other was identified. This subset was indicated as Front 1. Next, the same procedure was
197 performed on dataset A without the data points in F1. By performing this procedure iteratively, the
198 dataset was sorted into several fronts from F1 (best subset) to Fw (worst subset). For further

199 analysis we took 20% of patients with the lowest and highest front numbers and sorted them into
200 clusters A_1 and A_2 . For binary correlation-based feature selection the ratio $\ln(V2/\text{baseline})$ for
201 every determined physiological parameter was calculated and converted entries into rankings.
202 Rankings were normalized (mean of 0 and standard deviation of 1) and the mean and standard
203 deviation of the parameters was computed within each cluster. In this case, the mean describes the
204 level of deviation of a particular parameter within a cluster from the rest of the population, while
205 the standard deviation describes the level of concentration compared to the rest of the population.

206 **Data Sharing:**

207 This study did not generate new unique reagents. All new datasets will be made freely available at
208 the time of publication. Any additional information required to reanalyze the data reported in this
209 work is available from the corresponding author upon request. This paper does not report any
210 original code or algorithms. The code used in this study is freely available at
211 <https://www.ci.ovgu.de/Research/Codes.html> and on GitHub.

212 **RESULTS**

213 **Improved clinical outcome upon 6 months supplementation in PD patients**

214 A total of 72 patients were included and randomly assigned to receive 2FL+placebo,
215 PA+BA+placebo or a combination of 2FL+PA+BA. Study visits with detailed neurological
216 examination and sample collection were performed at the beginning of the study (baseline) and
217 after 3 (Visit1, V1) and 6 months (Visit2, V2) (Supplementary Fig. S1). Study groups were
218 comparable in terms of baseline variables (Supplementary Table S3). Supplementation was
219 generally well tolerated. One patient in the 2FL group discontinued treatment due to a mild
220 nontreatment-associated adverse event, hence no follow up data are available.

221 We assessed extrapyramidal motor function using the MDS-UPDRS III¹⁹ and LEED²⁰, olfactory
222 function using the Sniffin' Sticks test²¹ and cognitive function using the PANDA.²² All 3
223 interventions showed a decrease in MDS-UPDRS III scores and LEED over the period of 6 months
224 (Fig. 1A, B). Improvement in olfaction, however, was observed only in the 2FL and combination
225 group 2FL+BA+PA (Fig. 1C), while PANDA revealed an improvement in cognitive functions in
226 all groups (Fig. 1D). In sum, 6 months of supplementation with SCFA and/or 2FL improved motor
227 function, led to a reduction in the LEED required and positively impacted olfactory and cognitive
228 function in patients with PD.

229 **Gut microbiome diversity is not altered following supplementation**

230 We collected stool samples from all participants and performed shotgun metagenomic sequencing.
231 Supplementation did not change microbiome diversity or richness in any of the study groups (Fig.
232 2A,B) and concentrations of SCFA in fecal or serum samples were not elevated (Supplementary
233 Fig. S2). Thus, consistent with our previous study¹⁰, SCFA and/or 2FL supplementation did not
234 result in measurable alterations to gut microbiome composition.

235 **SCFA/2FL supplementation modulates immune cell subsets**

236 SCFAs have been shown to exert immunomodulatory effects;^{10, 23} therefore, we performed in-
237 depth characterization from cryopreserved peripheral blood mononuclear cells (PBMCs). We
238 detected changes in cell proportions across almost all subsets analyzed (Fig. 2C). Thus,
239 supplementation with 2FL and/or SCFA induces multifaceted alterations in the composition of the
240 peripheral immune compartment.

241 Since we have previously shown that SCFA improves mitochondrial respiration and restores the
242 suppressive function of regulatory T cells (Treg) in patients with multiple sclerosis (MS)¹⁰, we

243 recruited a validation cohort with n=4 PD patients receiving either 2FL or BA+PA. Maximal
244 respiration was significantly elevated after 14 days of supplementation (Fig. 2D), suggesting that
245 the intervention positively affected mitochondrial function. We did not detect any changes in Treg
246 suppressive capacity, but sorted Tregs showed an increase in the expression of the mitochondrial
247 genes (Supplementary Fig. S3A-C). We further assessed the functionality of Tregs by coculture
248 experiments with and without the addition of BA+PA *in vitro*. Secretion of pro-inflammatory
249 CXCL10 and IL2 was significantly decreased, while the levels of anti-inflammatory TGF β and
250 IL10 increased (Fig. 2E). In summary, SCFA supplementation improves mitochondrial respiration
251 in immunocytes, inhibits the release of proinflammatory mediators and increases the secretion of
252 anti-inflammatory mediators from immune cells.

253 **Distinct changes in immune cell subsets in responding patients**

254 While 6 months of supplementation improved motor function, this was not observed in all patients.
255 In every intervention group, there were few patients with unchanged or increasing MDS-UPDRS
256 III scores over time (Supplementary Fig. S3D). To gain insight into the mechanisms underlying
257 successful SCFA intervention, we combined all 3 intervention groups and stratified them into
258 responders (R: MDS-UPDRS III V2 < MDS-UPDRS III baseline) and nonresponders (NR: MDS-
259 UPDRS III V2 \geq MDS-UPDRS III baseline). We detected significant increases of CD4 T cells
260 after 6 months of intervention (Fig. 3A). Supplementation differentially affected subsets of CD4
261 T cells, with significantly increased Th1- and Th17 cells in the R and NR groups, while the levels
262 of Th2 cells were significantly reduced only in responding patients. The levels of B cells were also
263 significantly reduced both in the R and NR groups (Fig. 3B). Remarkably, the percentages of
264 mucosal-associated invariant T cells (MAIT), nonclassic and intermediate monocyte subsets only
265 significantly changed in responders (Fig. 3B). The percentages of other immune cell subsets were

266 not significantly altered. In summary, supplementation with 2FL and/or SCFA induces a multitude
267 of changes in the composition of immune cell subsets in the blood regardless of treatment response,
268 while increased numbers of MAIT cells and decreased numbers of nonclassic and intermediate
269 monocytes seem to correlate exclusively with intervention-induced clinical improvement.

270 **Multiobjective analysis reveals parameters associated with best response to intervention**

271 We initially defined responders and nonresponders by a reduction in MDS-UPDRS III after 6
272 months of supplementation. However, this method did not consider patients showing improvement
273 in olfactory and/or cognitive function or improvement in one score but worsening in another score.
274 Therefore, we devised an MOA to incorporate the various clinical measurements and thus more
275 accurately determine the response to intervention. We performed nondominated sorting on the
276 clinical parameter difference (V2 – baseline) with three metrics (objectives) olfactory score, MDS-
277 UPDRS III and PANDA. We selected the 20% of patients who had the lowest and highest front
278 numbers and sorted them into two clusters. These clusters included patients with the best/worst
279 response to intervention (Fig. 4A). One major feature in our dataset concerns the different scales
280 and distributions of the parameters, which makes it difficult to use existing statistical testing
281 methodologies²⁴. Therefore, we performed binary correlation-based feature selection to identify
282 the physiological parameters that have the strongest correlation with the best/worst response to
283 intervention. Using these two values, we identified the parameters with high levels of deviation
284 that also had low levels of variation within a cluster (Fig. 4B). This approach enabled the
285 identification of parameters associated with the best or worst combined clinical response (Fig. 4C).
286 This novel approach of MOA revealed additional immune cell subsets associated with response to
287 intervention. We identified CD4 Tfh cells as the parameter with the highest correlation to clinical
288 response (Fig. 4D). This association was not evident when immune cell data were stratified by

289 median split on MDS-UPDRS III (Fig. 4E). Thus, MOA is a promising novel approach to identify
290 parameters associated with response to intervention in complex datasets with several conflicting
291 metrics describing clinical outcome and a highly diverse repertoire of metrics recorded as potential
292 correlates.

293 **PD patients' microbiome before 2FL+BA+PA supplementation is associated with response**

294 To assess whether the response to supplementation was affected by the patients' microbiome, we
295 used baseline microbiome abundances, as they may hold a potential to predict the impact of
296 intervention. We devised a prediction model utilizing an XGBoost classifier. The model solely
297 uses baseline microbiome data as its inputs and outputs a prediction of the treatment response. The
298 model based on the microbiome of patients who received only 2FL or BA+PA had no predictive
299 capability. However, the model predicted response when it was established based on the baseline
300 microbiome of participants who received 2FL+BA+PA (Fig. 4F). We conducted SHapley Additive
301 exPlanations (SHAP) analysis (Fig. 4G) to understand which species had the greatest impact on
302 the model's prediction. Our analysis revealed that *Streptococcus* sp001556435 and *Agathobacter*
303 *rectalis* contributed to the prediction of nonresponders, whereas SFEL01 sp004557245 had a
304 significant impact on the prediction of responders. *Agathobacter rectalis* is a SCFA-producing
305 bacterium. Our study also revealed that the total abundance of SCFA-producing bacteria was
306 significantly different between responders and nonresponders who were treated with
307 2FL+BA+PA; responders had a lower abundance of SCFA-producing bacteria (Fig. 4H).

308 **DISCUSSION**

309 Here, we report that supplementation with SCFA improves clinical outcome in PD patients in a
310 randomized double-blind 6-month prospective study with 72 patients. To our knowledge, this is

311 the first exploratory study of SCFAs in PD patients showing improvement in motor and nonmotor
312 functions beyond the level provided by standard medication.

313 Collectively, improvements in hyposmia, motor and cognitive function as a result of SCFA
314 supplementation show that the intervention has a systemic impact on multiple brain regions.
315 Amelioration of motor and nonmotor symptoms suggests a neuroregenerative element of SCFA
316 supplementation. While we were not able to collect cerebrospinal fluid (CSF) in this study, we
317 have previously shown increased PA concentrations in CSF after supplementation in MS
318 patients.¹⁰ In addition, free fatty acid receptor 3 is expressed on the human brain endothelium, and
319 its interaction protects the BBB from oxidative stress.²⁵ Thus, supplementation with SCFAs may
320 also directly impact the BBB and CNS to promote neuroregeneration.

321 Supplementation did not alter microbial composition. Even though microbial dysbiosis has been
322 reported in PD patients, our results suggest that amelioration of disease symptoms by SCFA and/or
323 2FL supplementation does not require profound changes in gut microbe populations. The SCFA
324 concentration in fecal samples also remained unaffected by supplementation, suggesting that
325 excess SCFA is not excreted via stool. Over 95% of SCFAs produced in the colon are absorbed
326 by the gut mucosa in healthy individuals²⁶ or transported via the portal vein to the liver, preventing
327 escape into the systemic circulation.²⁷ Since SCFAs are not passed in the stool and serum levels
328 only marginally increase, SCFAs are most likely swiftly metabolized.

329 Supplementation led to a significant increase in MAIT cells only in responding patients. At barrier
330 surfaces, MAIT cells play an important role in the crosstalk between the host and the
331 microbiome.²⁸ Importantly, a regulatory role for MAIT cells in neuroinflammation through
332 suppression of pathogenic Th1 cells has been shown,²⁹ and reduced numbers of MAIT cells in
333 peripheral blood have been reported in patients with several autoimmune diseases.³⁰ A shift toward

334 proinflammatory states in monocyte populations with a decrease in the levels of classic subsets
335 and an increase in the levels of intermediate subsets with increased HLA-DR expression has been
336 shown in PD,³¹ and a large study on expression quantitative trait loci (eQTL) revealed the
337 overrepresentation of PD-related genes in monocyte populations.³² Decreased absolute counts of
338 Tfh cells have also recently been reported in PD patients,³³ in addition to decreased numbers of
339 circulating anti-inflammatory B-cell subsets, thus implicating defective B-cell regulation as
340 another contributing factor in PD. In summary, we propose that supplementation with SCFAs acts
341 in concert on innate-like lymphoid cells, monocytes and B cells to promote a reduced inflammatory
342 immune response in PD patients.

343 Our prediction model suggests that the patient microbiome can predict the efficacy of 2FL and
344 BA+PA supplementation. Specifically, the composition of the SCFA-producing gut microbiota
345 affected the response, with responders having less SCFA-producing gut microbes, which could
346 help explain why supplementation with SCFA induces a greater response rate among them. If
347 validated in larger studies, such a model can help evaluate the chances of a specific patient
348 benefitting from intervention before it is started. In summary, SCFA supplementation may be a
349 promising disease-modifying strategy in PD, hence, a follow-up phase III clinical trial to
350 investigate the therapeutic potential of SCFAs in PD is warranted.

351 **Acknowledgment:**

352 We thank Cathrine Husberg from BASF for her scientific contribution and energetic support. We
353 thank Bärbel Henke from the Clinic of Neurology II, Hattingen for archiving the biomaterials. We
354 thank Grazyna Debska-Vielhaber from the Department of Neurology, Magdeburg, for performing
355 the seahorse assay. The help of Roland Hartig from the multiparametric bioimaging and cytometry

356 platform (MPBIC) of the Otto-von-Guericke University Magdeburg with FACS Aria cell sorting
357 is greatly acknowledged.

358 **Author's Roles:**

359 Conceptualization: TH, AD, CD, UOJ, RG, HP, NY, AH

360 Methodology: TH, AD, CD, GIS, FH, SK, AM, NY, AH

361 Software: MS, QS, SM, ES, NY

362 Formal Analysis: TH, AD, CD, SF, MS, QS, GIS, FH, SK, AM, CAD, NT, AZ, IES, SM, ES,
363 NY, AH

364 Investigation: TH, AD, CD, SF, MS, FH, AM, LMW, JP, DJ, CAD

365 Resources: UOJ, SOH

366 Data Curation: TH, AD, CD, SF, MS, QS, LMW, JP, DJ, SM, ES, NY, AH

367 Writing – Original Draft: TH, AD, CD, NY, AH

368 Writing – Review & Editing: TH, AD, CD, MS, GIS, AZ, IES, SM, HP, ES, NY, AH

369 Visualization: TH, AD, CD, SF, MS, QS, NY, AH

370 Supervision: RG, HP, ES, NY, AH

371 Project Administration: TH, AD, CD, HP, AH

372 Funding Acquisition: UOJ, SOH, HP, AH

373 **REFERENCES**

374 1. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nat Rev Dis Primers* 2017;3:17013.

375 2. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. *Nat Rev*
376 *Neurosci* 2017;18(8):509.

377 3. Zinocker MK, Lindseth IA. The Western Diet-Microbiome-Host Interaction and Its Role in
378 Metabolic Disease. *Nutrients* 2018;10(3).

- 379 4. Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological
380 disorders. *Lancet Neurol* 2020;19(2):179-194.
- 381 5. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with
382 sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's
383 disease. *PLoS One* 2011;6(12):e28032.
- 384 6. Nie S, Wang J, Deng Y, Ye Z, Ge Y. Inflammatory microbes and genes as potential biomarkers
385 of Parkinson's disease. *NPJ Biofilms Microbiomes* 2022;8(1):101.
- 386 7. Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the
387 Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. *NPJ*
388 *Parkinsons Dis* 2021;7(1):27.
- 389 8. Visconti A, Le Roy CI, Rosa F, et al. Interplay between the human gut microbiome and host
390 metabolism. *Nat Commun* 2019;10(1):4505.
- 391 9. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ
392 between patients with Parkinson's disease and age-matched controls. *Parkinsonism Relat Disord*
393 2016;32:66-72.
- 394 10. Duscha A, Gisevius B, Hirschberg S, et al. Propionic Acid Shapes the Multiple Sclerosis
395 Disease Course by an Immunomodulatory Mechanism. *Cell* 2020;180(6):1067-1080 e1016.
- 396 11. Hall DA, Voigt RM, Cantu-Jungles TM, et al. An open label, non-randomized study
397 assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. *Nat*
398 *Commun* 2023;14(1):926.
- 399 12. Suligoj T, Vigsnaes LK, Abbeele PVD, et al. Effects of Human Milk Oligosaccharides on
400 the Adult Gut Microbiota and Barrier Function. *Nutrients* 2020;12(9).

- 401 13. Leviatan S, Shoer S, Rothschild D, Gorodetski M, Segal E. An expanded reference map of
402 the human gut microbiome reveals hundreds of previously unknown species. *Nat Commun*
403 2022;13(1):3863.
- 404 14. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. *Proceedings of the 22nd*
405 *ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*. San
406 Francisco, California, USA: Association for Computing Machinery; 2016. p. 785–794.
- 407 15. Wang XW, Liu YY. Comparative study of classifiers for human microbiome data. *Med*
408 *Microecol* 2020;4.
- 409 16. Lundberg SM, Erion GG, Lee S-I. Consistent Individualized Feature Attribution for Tree
410 Ensembles. *ArXiv* 2018;abs/1802.03888.
- 411 17. Monaco G, Lee B, Xu W, et al. RNA-Seq Signatures Normalized by mRNA Abundance
412 Allow Absolute Deconvolution of Human Immune Cell Types. *Cell Rep* 2019;26(6):1627-1640
413 e1627.
- 414 18. Deb K, Agrawal S, Pratap A, Meyarivan T. A Fast Elitist Non-dominated Sorting Genetic
415 Algorithm for Multi-objective Optimization: NSGA-II. 2000; Berlin, Heidelberg: Springer Berlin
416 Heidelberg. p. 849-858.
- 417 19. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision
418 of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and
419 clinimetric testing results. *Mov Disord* 2008;23(15):2129-2170.
- 420 20. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa
421 dose equivalency reporting in Parkinson's disease. *Mov Disord* 2010;25(15):2649-2653.
- 422 21. Cavaco S, Goncalves A, Mendes A, et al. Abnormal Olfaction in Parkinson's Disease Is
423 Related to Faster Disease Progression. *Behav Neurol* 2015;2015:976589.

- 424 22. Michels J, van der Wurp H, Kalbe E, et al. Long-Term Cognitive Decline Related to the
425 Motor Phenotype in Parkinson's Disease. *J Parkinsons Dis* 2022;12(3):905-916.
- 426 23. Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell
427 function by short-chain fatty acids. *Clin Transl Immunology* 2016;5(4):e73.
- 428 24. Lualdi M, Fasano M. Statistical analysis of proteomics data: A review on feature selection.
429 *J Proteomics* 2019;198:18-26.
- 430 25. Hoyles L, Snelling T, Umlai UK, et al. Microbiome-host systems interactions: protective
431 effects of propionate upon the blood-brain barrier. *Microbiome* 2018;6(1):55.
- 432 26. Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and
433 gastrointestinal physiology and function. *Br J Nutr* 1998;80 Suppl 1:S147-171.
- 434 27. Bloemen JG, Venema K, van de Poll MC, Olde Damink SW, Buurman WA, Dejong CH.
435 Short chain fatty acids exchange across the gut and liver in humans measured at surgery. *Clin Nutr*
436 2009;28(6):657-661.
- 437 28. Amini A, Pang D, Hackstein CP, Klenerman P. MAIT Cells in Barrier Tissues: Lessons from
438 Immediate Neighbors. *Front Immunol* 2020;11:584521.
- 439 29. Miyazaki Y, Miyake S, Chiba A, Lantz O, Yamamura T. Mucosal-associated invariant T
440 cells regulate Th1 response in multiple sclerosis. *Int Immunol* 2011;23(9):529-535.
- 441 30. Mechelli R, Romano S, Romano C, et al. MAIT Cells and Microbiota in Multiple Sclerosis
442 and Other Autoimmune Diseases. *Microorganisms* 2021;9(6).
- 443 31. Thome AD, Atassi F, Wang J, et al. Ex vivo expansion of dysfunctional regulatory T
444 lymphocytes restores suppressive function in Parkinson's disease. *NPJ Parkinsons Dis*
445 2021;7(1):41.

446 32. Raj T, Rothamel K, Mostafavi S, et al. Polarization of the effects of autoimmune and
447 neurodegenerative risk alleles in leukocytes. *Science* 2014;344(6183):519-523.

448 33. Li R, Tropea TF, Baratta LR, et al. Abnormal B-Cell and Tfh-Cell Profiles in Patients With
449 Parkinson Disease: A Cross-sectional Study. *Neurol Neuroimmunol Neuroinflamm* 2022;9(2).

450

451 **Tables and Figure Legends**

452 **Fig. 1. Improved clinical outcome upon supplementation.** Clinical parameters determined at
453 the first study visit (Baseline) and at the three (V1) and six (V2) month follow-ups. (A) MDS-
454 UPDRS III, (B) LEDD, (C) olfactory score and (D) PANDA. Data plotted as before-after for each
455 patient (gray) and mean (black) \pm SEM. Tested by 2-way ANOVA (C, D) or mixed effects analysis
456 (E, F). **** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$.

457 **Fig. 2. Effect of supplementation on the gut microbiome and immune cells.** Shotgun
458 metagenomic sequencing of $n=71$ stool samples. (A) Shannon diversity, (B) richness of gut
459 microbiota at baseline and V2. (C) Ratio of immune subsets at baseline (red) and 6 months (V2,
460 blue). Mean (solid line) \pm SD (dashed lines), all interventions pooled. (D) Mitochondrial
461 respiration; validation cohort at baseline (V0) and after 14 days of (V1, $n=3$ 2FL or BA+PA). Left:
462 Oxygen-consumption rate (OCR) over time, middle: Maximal and right: Basal respiration, mean
463 \pm SD, significance determined by T test. (E) Treg/PBMC coculture assay of $n=5$ healthy controls
464 (HC) or PD patients, *in vitro* addition of BA+PA. Data presented as mean \pm SD, significance
465 determined by Friedman multiple comparisons test.

466 **Fig. 3. Supplementation differentially affects immune cell subsets in responding patients.** (A)
467 Proportions of CD4-, Th1-, Th17- and Th2 T cells among PBMCs, depicted as median split MDS-

468 UPDRS III responder/nonresponder, matched baseline and V2, mean \pm SEM. Significance was
469 determined by paired T test. **(B)** Proportions of B cells, MAIT, nonclassic and intermediate
470 monocyte populations in PBMCs depicted as median split MDS-UPDRS III
471 responder/nonresponder, matched baseline and V2, mean \pm SEM. Significance was determined by
472 paired T test. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$.

473 **Fig. 4. Multiobjective analysis and prediction modeling reveal parameters associated with**
474 **the best/worst response to intervention.** **(A)** Nondominated sorting based on olfactory score,
475 MDS-UPDRS III and PANDA (V2 – baseline). The clusters of patients with the best (red) and
476 worst (blue) 20% performances. **(B)** Examples of an uncorrelated (upper panel) and a correlated
477 parameter (lower panel). Solid points depict ranking (not to scale), and transparent points the raw
478 values, data points in the best cluster (red). Mean of all rankings (solid black line) and mean only
479 in the best cluster (dashed red line). **(C)** Nondominated ranking of physiological parameters
480 associated with the best/worst response. **(D)** Proportions of CD4 Tfh cells from patients within the
481 best and worst clusters, matched baseline and V2, black line mean \pm SEM. **(E)** Proportions of CD4
482 Tfh cells in all patients, median split MDS-UPDRS III responder/nonresponder, matched baseline
483 and V2, black line mean \pm SEM. Significance was determined by paired T test. **(F)** Prediction
484 model for distinguishing R from NR: ROC curve of a prediction model based solely on
485 microbiome baseline features (blue). **(G)** SHAP analysis of the model. **(H)** Abundances of SCFA-
486 producing bacteria before supplementation with 2FL+BA+PA, * $p < 0.05$.

487 **Supplementary Fig. S1.** CONSORT 2010 flow diagram. CONSolidated Standards of Reporting
488 Trials: Schematic representation of the randomized double-blind prospective study.

489 **Supplementary Fig. S2. SCFA concentration in stool and serum is not altered after**
490 **supplementation.** Concentrations of PA and BA in stool **(A)** and in serum **(B)** samples measured

491 by HPLC–MS/MS. Data are plotted as before-after for each patient (gray) and mean (black) +/-
492 SEM. Tested by 2-way ANOVA with Sidak’s multiple comparisons test.


493 **Supplementary Fig. S3: Supplementation with SCFA does not boost the suppressive capacity**
494 **of Tregs but increases the expression of mitochondrial genes.** (A) Treg/PBMC suppression
495 assay at baseline (V0) and 14-day follow-up (V1), samples from validation cohort; MACS-sorted
496 cells. (B, C) Gene expression in sorted Tregs from validation cohort; FACS-sorted cells. (B)
497 Heatmap of fold changes follow-up (V1) and (C) individual $2^{-\Delta\text{CT}}$ values for *Crot* and *Xpa*.
498 Housekeeping *B2m*, time points compared by Wilcoxon matched pairs test. (D) Responders (R:
499 MDS-UPDRS III V2 < MDS-UPDRS III baseline) and nonresponders (NR: MDS-UPDRS III V2
500 \geq MDS-UPDRS III baseline) stratified by group. Data plotted as heatmap (ratio V2/baseline) and
501 MDS-UPDRS III before-after for each patient; responders (blue) and nonresponders (pink).

502 **Supplementary Table S1:** List of antibodies used for in-depth immunophenotyping.

503 **Supplementary Table S2:** Gating strategies for in-depth immuno-phenotyping of immune cell
504 subsets. Adapted from Monaco et al.¹⁷.

505 **Supplementary Table S3. Demographic data and characteristics of patients prior to**
506 **therapeutic intervention.** Main demographics and clinical and treatment characteristics of
507 participants at study entry. Data are presented as the mean \pm SD or n (%).

Figure 1









Figure 3






Figure 4




Supplementary Figure S1


CONSORT 2010 Flow Diagram



Supplementary Figure S2



Supplementary Figure S3



Surface Marker	Clone	Fluorochrome	Company	Cat-Nr.	Panel
CD3	UCHT1	FITC	BioLegend	300440	1, 2, 4
CD4	RPAT4	APC Fire 750	BioLegend	300560	1
CD25	M-A251	BV785	BioLegend	356140	1
CD127	A019D5	APC	BioLegend	351316	1
CXCR5	J25204	PE/Dazzle 594	BioLegend	356928	1
CD45RA	H100	BV605	BioLegend	304134	1,2
CCR7	G043H7	PerCP/Cy5.5	BioLegend	353220	1,2
CCR6	11A9	PE	BD	559562	1
CXCR3	G025H7	BV650	BioLegend	353730	1
CCR4	L2A1H4	BV421	BioLegend	359414	1
CD8	SK1	APC Fire 750	BioLegend	344746	2
CD161	HP3G10	PE	BioLegend	339904	2
V α 7.2	3C10	BV785	BioLegend	351722	2
TCR γ/δ	11F2	APC	Miltenyi	130-113-500	2
V α 2	B6	BV421	BioLegend	331428	2
CD19	H1B19	FITC	BioLegend	302206	3, 4
IgD	1A6-2	PE/Dazzle 594	BioLegend	348240	3
CD45	H130	Alexa Fluor 700	BioLegend	304024	3, 4
CD27	323	BV421	BioLegend	302824	3
CD38	HIT2	APC	BioLegend	303510	3
CD34	563	PE	BD	550761	3
CD11c	B-LY6	APC	BD	559877	4
CD14	HCD14	PE/Dazzle 594	BioLegend	325634	4
CD16	3G8	APC Fire 750	BioLegend	302060	4
CD56	HCD56	PerCP/Cy5.5	BioLegend	318322	4
CD11b	ICRF44	PE	BioLegend	301306	4
CD123	6H6	BV605	BioLegend	306026	4
HLA-DR	L243	BV785	BioLegend	307642	4

Supplementary table S1: List of antibodies used for in-depth immunophenotyping.

Panel 1 - CD4 T cells			
Cell type	Gating strategy		
CD4+ T cells T follicular helper (Tfh) T regulatory cells (Tregs) T helper 1 (Th1) T helper 1/T helper 17 (Th1/17) T helper 17 (Th17) T helper 2 (Th2) T CD4 terminal effector (TE) T CD4 Naïve	CD3 ⁺ CD4 ⁺	CXCR5 ⁺ CXCR5 ⁻ CD25 ^{high} CD127 ^{low} CXCR5 ⁻ CD127 ⁺ CD25 ^{-/low} CXCR3 ⁺ CCR6 ⁻ CXCR5 ⁻ CD127 ⁺ CD25 ^{-/low} CXCR3 ⁺ CCR6 ⁺ CXCR5 ⁻ CD127 ⁺ CD25 ^{-/low} CXCR3 ⁻ CCR6 ⁺ CXCR5 ⁻ CD127 ⁺ CD25 ^{-/low} CXCR3 ⁻ CCR6 ⁻ CCR4 ⁺ CXCR5 ⁻ CD127 ⁺ CD25 ^{-/low} CXCR3 ⁻ CCR6 ⁻ CCR4 ⁻ CCR7 ⁻ CD45RA ^{low} CXCR5 ⁻ CD127 ⁺ CD25 ^{-/low} CXCR3 ⁻ CCR6 ⁻ CCR4 ⁻ CCR7 ⁺ CD45RA ^{high}	
Panel 2 - CD8, γ/δ and MAIT T cells			
Cell type	Gating strategy		
CD8+ T cells γ/δ Vd2 ⁺ (T γ/δ Vd2+) γ/δ Vd2 ⁻ (T γ/δ non-Vd2+) MAIT T CD8 Naïve T CD8 central memory (CM) T CD8 effector memory (EM) T CD8 terminal effector (TE)	CD3 ⁺	TCR γ/δ ⁻ TCR γ/δ ⁺ TCR γ/δ ⁻ Vd2 ⁻ CD8 ⁺ TCR γ/δ ⁻ Vd2 ⁻	CD16 ^{high} NOT V α 7.2 ⁺ Vd2 ⁺ Vd2 ⁻ V α 7.2 ⁺ CD161 ^{high} CCR7 ⁺ CD45RA ⁺ CCR7 ⁺ CD45RA ⁻ CCR7 ⁻ CD45RA ⁻ CCR7 ⁻ CD45RA ⁺
PANEL 3 - B cells and Progenitors			
Cell type	Gating strategy		
Progenitors Total B cells (B cells) Naïve B cells (B naïve) Nonswitched memory B cells (B NSM) Exhausted B cells (B EX) Switched memory B cells (BSM) Plasmablasts	CD45 ⁺	CD34 ⁺ CD45 ^{low} CD19 ⁺ CD34 ⁻	CD27 ⁻ IgD ⁺ CD27 ⁺ IgD ⁺ CD27 ⁻ IgD ⁻ CD27 ⁺ IgD ⁻ CD38 ^{low} CD27 ⁺ IgD ⁻ CD38 ^{high}
Panel 4 - Monocytes, DCs, NK cells, Low-density basophils			
Cell type	Gating strategy		
NK cells Classic (C) monocytes Intermediate (I) monocytes Nonclassic (NC) monocytes Myeloid dendritic cells (mDCs) Plasmacytoid dendritic cells (pDCs) Low-density (LD) basophils	CD45 ⁺ CD3 ⁻ CD19 ⁻	CD11c ⁺ CD16 ⁻ CD56 ⁻	CD16 ^{+/-} CD56 ^{+/low} CD14 ⁻ CD11c ⁻ CD14 ⁺ CD16 ⁻ CD14 ⁺ CD16 ⁺ CD14 ^{low} CD16 ⁺ HLA-DR ⁺ CD11c ⁺ CD123 ^{low} HLA-DR ⁺ CD11c ⁻ CD123 ⁺ HLA-DR ⁻ CD123 ⁺ CD11b ⁺

Supplementary table S2: Gating strategies for in-depth immuno-phenotyping of immune cell subsets. Adapted from Monaco et al. (17).

Characteristics	PA+BA+placebo (n=24)	2FL+placebo (n=24)	2FL+PA+BA (n=24)
Female sex	13 (54.2%)	9 (37.5%)	13 (54.2%)
Age, years	62(±9)	67 (±12)	65 (±8)
Duration of disease, years	7 (±7)	6 (±6)	4 (±4)
BMI	26 (±4)	26 (±3)	25 (±3)
Subgroups			
akinetic-rigid	8 (33.3%)	9 (37.5%)	11 (45.8%)
equivalent	14 (58.3%)	12 (50%)	12 (50%)
tremordominant	2 (8.3 %)	3 (12.5%)	1 (4.17%)
Medication			
LEDD [mg]	770 (±302)	785 (±267)	756 (±261)
95% CI	642.1-897.1	672.2-897.3	646-866.5
Benserazide	24 (100%)	22 (91.7%)	23 (95.8%)
Carbidopa	4 (16.7%)	5 (20.8%)	2 (8.3%)
Piribedil	2 (8.3%)	0	2 (8.3%)
Rotigotine	2 (8.3%)	3 (12.5%)	3 (12.5%)
Ropinirole	2 (8.3%)	1 (4.17%)	2 (8.3%)
Pramipexole	4 (16.7%)	2 (8.3%)	4 (16.7%)
Rasagiline	13 (54.2%)	8 (33.3%)	14 (58.3%)
Selegiline	3 (12.5%)	9 (37.5%)	3 (12.5%)
Safinamide	2 (8.3%)	1 (4.2%)	2 (8.3%)
COMT-inhibitor	6 (25%)	8 (33.3%)	9 (37.5%)
Amantadine	2 (8.3 %)	2 (8.3 %)	1 (4.2%)
Apomorphine	0	0	0
Anticholinergics	0	1 (4.2%)	0
Clozapine	1 (4.2%)	0	2 (8.3%)
Quetiapine	1 (4.2%)	3 (12.5%)	1 (4.2%)
MDS-Unified Parkinson's Disease Rating Scale			
MDS-UPDRS I	10 (±10)	17 (±12)	17 (±13)
95% CI	12.6-21	12.1-22.5	11.2-22.1
MDS-UPDRS II	9 (±6)	9 (±8)	10 (±9)
95% CI	6.8-12.1	6.3-12.7	6-13.4
MDS-UPDRS III	29 (±17)	33 (±16)	30 (±16)
95% CI	22.1-36.3	26.3-40	23-36.8
MDS-UPDRS IV	3 (± 3)	5 (±5)	3 (±3)
95% CI	1.8-4.2	2.5-6.3	1.4-4.1
Hoehn & Yahr scale	2 (±1)	2 (±1)	2 (±1)
95% CI	1.9-2.5	1.9-2.4	1.9-2.7
PANDA	25 (±4)	33 (±16)	30 (±16)
95% CI	23.7-26.7	18.9-24.8	20.8-26.1
Olfactory score	8 (±3)	7 (±3)	7 (±3)
95% CI	6.8-9	5.9-8.1	5.6-8.1

Supplementary table S3: Demographic data.